News & Updates

Among Asians with type 2 diabetes (T2D), users of sodium-glucose cotransporter-2 (SGLT2) inhibitors may have better kidney outcomes compared with those who use other glucose-lowering drugs.

Treatment with ensitrelvir among household contacts (HHC) of index patients (IP) with COVID-19 within 72 h after the onset of IP symptoms demonstrates efficacy and an acceptable safety profile as postexposure prophylaxis (PEP) in SCORPIO-PEP, a phase III placebo-controlled trial.

A phase IIa study affirms the tolerable safety of a combination regimen comprising three investigational compounds – two broadly neutralizing antibodies (bNAbs), VRC07-523LS and CAP256V2LS, and the TLR7 agonist vesatolimod – in women with HIV-1.